Business Context and Reporting Period
Company: MEDNAX, Inc. (Successor to Pediatrix Medical Group, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2009
Business Overview: MEDNAX is a leading provider of physician services, including neonatal, maternal-fetal, pediatric subspecialty, and anesthesia care. As of December 31, 2009, the company operated a national network of 1,484 affiliated physicians across 33 states and Puerto Rico, primarily staffing hospital-based Neonatal Intensive Care Units (NICUs). The company completed a holding company formation transaction effective December 31, 2008, establishing MEDNAX, Inc. as the parent of Pediatrix.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Net Patient Service Revenue | $1,288.3 million | $1,068.3 million |
| Income from Operations | $288.9 million | $242.0 million |
| Net Income | $175.8 million | $169.2 million |
| Diluted EPS (Continuing Ops) | $3.78 | $3.11 |
| Operating Margin | 22.4% | 22.7% |
| Cash and Cash Equivalents | $26.5 million | $14.3 million |
| Working Capital | ($54.0 million) Deficit | ($32.2 million) Deficit |
| Line of Credit Outstanding | $50.0 million | $139.5 million |
| Goodwill | $1,270.1 million | $1,128.0 million |
Material Changes vs. Prior Period
- Revenue Growth: Net patient service revenue increased 20.6% ($220.0 million) year-over-year. Approximately 77% of this increase ($169.5 million) was attributable to acquisitions completed after December 31, 2007. Same-unit revenue grew 5.1%, driven by higher patient volumes and improved managed care contracting.
- Acquisitions: The company acquired 11 physician group practices in 2009, including seven neonatal practices, one multi-state pediatric subspecialty group, one maternal-fetal practice, one pediatric cardiology practice, and one anesthesiology practice.
- Profitability: Net income increased 3.9% to $175.8 million. This growth occurred despite a slight decrease in operating margin (from 22.7% to 22.4%), which management attributed to the addition of anesthesiology services and office-based practices that currently have lower margins than neonatal services.
- Discontinued Operations: Unlike 2008, which included a $22.0 million after-tax gain from the sale of the newborn metabolic screening laboratory business, 2009 had no income from discontinued operations.
- Liquidity: Cash flow from operating activities improved to $241.4 million in 2009 from $181.4 million in 2008. Days Sales Outstanding (DSO) improved from 50.2 days to 45.4 days.
Guidance, Outlook, and Risks
- Outlook: Management anticipates an effective tax rate of approximately 38.9% for 2010. The company plans to invest approximately $100 million in acquisitions within neonatal, maternal-fetal, and pediatric cardiology specialties in 2010, with additional, undetermined investment in anesthesiology.
- Economic Risks: The company notes that the U.S. economic slowdown and high unemployment may shift payor mix toward government-sponsored programs (Medicaid/Medicare), which reimburse at lower rates than commercial payors. State budget shortfalls could also lead to reduced or delayed Medicaid funding.
- Regulatory Risks: The company is subject to extensive federal and state regulations, including the False Claims Act, Anti-Kickback Statute, and Stark Law. It is under a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG) following a 2006 settlement regarding billing practices. Failure to comply could result in exclusion from government programs.
- Legal Proceedings: The company settled an SEC investigation regarding stock option granting practices in March 2009 without paying a civil penalty. It continues to cooperate with the U.S. Attorney's office regarding the same matter. The company also faces routine medical malpractice claims, for which it maintains professional liability insurance and self-insures a portion of the risk.
Investor Verification Checklist
- Payor Mix Shift: Verify the trend of revenue shifting from commercial payors to government programs (Medicaid/Medicare) and its impact on reimbursement rates and contractual adjustments.
- Acquisition Integration: Assess the financial performance of the 11 practices acquired in 2009 and the company's ability to integrate them to achieve projected operating efficiencies.
- Regulatory Compliance: Monitor the status of the Corporate Integrity Agreement with the OIG and any new government audits or investigations regarding billing practices.
- Professional Liability Reserves: Review the adequacy of the $109.6 million accrued liability for professional liability risks, noting the inherent uncertainty in actuarial estimates for claims incurred but not reported.
- Geographic Concentration: Note that Texas alone accounted for approximately 24% of net patient service revenue in 2009, creating exposure to state-specific regulatory and economic changes.